论文部分内容阅读
目的探讨TCT联合HPV-DNA在筛查宫颈病变中的应用价值。方法对2008年1月至2009年12月就诊于郑州市第三人民医院妇科门诊1060例患者行宫颈液基细胞学(TCT)和宫颈HPV-DNA的筛查,采取TBS报告方式,对ASC-US以上的患者和(或)HPV-DNA检测阳性的患者行宫颈活检。结果 1060例TCT检查的患者中,ASC-US以上者235例,HPV阳性者282例,其阳性检出率分别为22.17%、26.60%;TCT和HPV-DNA均阳性者186例,占15.75%,病理结果示宫颈浸润性鳞癌6例,CINⅠ是92例,CINⅡ-Ⅲ为65例,分别为0.57%,8.68%,6.13%。结论 TCT联合HPV-DNA能提高宫颈病变的检出率,可作为宫颈病变的筛查诊断方法。
Objective To investigate the value of TCT combined with HPV-DNA in the screening of cervical lesions. Methods From January 2008 to December 2009, 1060 cases of cervical cytology-based cytology (TCT) and cervical HPV-DNA screening in 1060 gynecological clinics of the Third People’s Hospital of Zhengzhou City were screened. The TBS reporting method was used to detect the expression of ASC- Cervical biopsy was performed on patients with US or higher and / or HPV-DNA positive tests. Results Of the 1060 patients with TCT, 235 were ASC-US and 282 were HPV-positive. The positive rates were 22.17% and 26.60%, respectively; 186 were positive for TCT and HPV-DNA, accounting for 15.75% The pathological results showed that there were 6 cases of invasive squamous cell carcinoma of the cervix. There were 92 cases of CINⅠ and 65 cases of CINⅡ-Ⅲ, which were 0.57%, 8.68% and 6.13% respectively. Conclusion TCT combined with HPV-DNA can improve the detection rate of cervical lesions, which can be used as a screening diagnostic method for cervical lesions.